Author: Emily R Adams; Rekha Anand; Monique I Andersson; Kathryn Auckland; J Kenneth Baillie; Eleanor Barnes; John Bell; Tamsin Berry; Sagida Bibi; Miles Carroll; Senthil Chinnakannan; Elizabeth Clutterbuck; Richard J Cornall; Derrick W Crook; Thushan De Silva; Wanwisa Dejnirattisai; Kate E Dingle; Christina Dold; David W Eyre; Helen Farmer; Sarah J Hoosdally; Alistair Hunter; Katie Jeffrey; Paul Klenerman; Julian Knight; Clarice Knowles; Andrew J Kwok; Ullrich Leuschner; Chang Liu; Cesar Lopez-Camacho; Philippa C Matthews; Hannah McGivern; Alexander J Mentzer; Jonathan Milton; Juthathip Mongkolsapaya; Shona C Moore; Marta S Oliveira; Fiona Pereira; Timothy Peto; Rutger J Ploeg; Andrew Pollard; Tessa Prince; David J Roberts; Justine K Rudkin; Gavin R Screaton; Malcolm G Semple; Donal T Skelly; Elliot Nathan Smith; Julie Staves; David Stuart; Piyada Supasa; Tomas Surik; Pat Tsang; Lance Turtle; A Sarah Walker; Beibei Wang; Charlotte Washington; Nicholas Watkins; James Whitehouse; Sally Beer; Robert Levin; Alexis Espinosa; Dominique Georgiou; Jose Carlos Martinez Garrido; Hannah Thraves; Elena Perez Lopez; Maria del Rocio Fernandez Mendoza; Alberto Jose Sobrino Diaz; Veronica Sanchez
Title: Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays Document date: 2020_4_20
ID: 5trox1i5_28
Snippet: We here present the performance characteristics of a novel ELISA and nine LFIA devices for detecting SARS-COV-2 IgM and IgG using a panel of reference plasma. After setting thresholds for detection using 50 negative (pre-pandemic) controls, 85% of 40 RT-PCR-confirmed positive patients had IgG detected by ELISA, including 100% patients tested ≥10 days after symptom onset. A panel of LFIA devices had sensitivity between 55 and 70% against the ref.....
Document: We here present the performance characteristics of a novel ELISA and nine LFIA devices for detecting SARS-COV-2 IgM and IgG using a panel of reference plasma. After setting thresholds for detection using 50 negative (pre-pandemic) controls, 85% of 40 RT-PCR-confirmed positive patients had IgG detected by ELISA, including 100% patients tested ≥10 days after symptom onset. A panel of LFIA devices had sensitivity between 55 and 70% against the referencestandard RT-PCRs, or 65-85% against ELISA, with specificity of 95-100% and 93-100% respectively. These estimates come with relatively wide confidence intervals due to constraints on the number of devices made available for testing. Nevertheless, this study provides a benchmark against which to further assess the performance of platforms to detect anti-SARS-CoV-2 IgM/IgG, with the aim of guiding decisions about deploying antibody testing and informing the design and assessment of second-generation assays.
Search related documents:
Co phrase search for related documents- anti sars and ELISA detect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- anti sars and IgG SARS IgM detect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- anti sars and lfia device: 1
- anti sars and PCR confirm: 1, 2, 3, 4, 5, 6
- anti sars and performance characteristic: 1
- anti sars and positive patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- anti sars and reference plasma: 1
- anti sars and reference plasma panel: 1
- anti sars and RT PCR confirm: 1, 2, 3, 4
- anti sars and second generation: 1
- anti sars IgM IgG detect and IgG SARS IgM detect: 1, 2, 3, 4, 5, 6, 7
- antibody testing and confidence interval: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- antibody testing and ELISA detect: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antibody testing and IgG SARS IgM detect: 1, 2, 3, 4
- antibody testing and lfia device: 1
- antibody testing and PCR confirm: 1, 2
- antibody testing and performance characteristic: 1
- antibody testing and positive patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antibody testing and reference plasma: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date